These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6352863)

  • 21. Effects of specific monoclonal antibodies on La Crosse virus neutralization: aggregation, inactivation by Fab fragments, and inhibition of attachment to baby hamster kidney cells.
    Kingsford L; Boucquey KH; Cardoso TP
    Virology; 1991 Feb; 180(2):591-601. PubMed ID: 1703370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies against the G1 and nucleocapsid proteins of LaCrosse and Tahyna viruses.
    Gonzalez-Scarano F; Shope RE; Calisher CH; Nathanson N
    Prog Clin Biol Res; 1983; 123():145-56. PubMed ID: 6191341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenic analysis of Punta Toro virus and identification of protective determinants with monoclonal antibodies.
    Pifat DY; Osterling MC; Smith JF
    Virology; 1988 Dec; 167(2):442-50. PubMed ID: 2462308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. La Crosse virus G1 glycoprotein undergoes a conformational change at the pH of fusion.
    Gonzalez-Scarano F
    Virology; 1985 Jan; 140(2):209-16. PubMed ID: 3881876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and antigenic comparison of the envelope glycoproteins of Venezuelan equine encephalomyelitis virus strains.
    France JK; Wyrick BC; Trent DW
    J Gen Virol; 1979 Sep; 44(3):725-40. PubMed ID: 119035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation and intracellular transport of a heterodimeric viral spike protein complex.
    Persson R; Pettersson RF
    J Cell Biol; 1991 Jan; 112(2):257-66. PubMed ID: 1988460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serodiagnosis of La Crosse virus infections in humans by detection of immunoglobulin M class antibodies.
    Calisher CH; Pretzman CI; Muth DJ; Parsons MA; Peterson ED
    J Clin Microbiol; 1986 Apr; 23(4):667-71. PubMed ID: 3700625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudotype formation with La Crosse virus glycoproteins.
    Bupp K; González-Scarano F
    J Gen Virol; 1998 Apr; 79 ( Pt 4)():667-71. PubMed ID: 9568959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the intracellular transport properties of recombinant La Crosse virus glycoproteins.
    Bupp K; Stillmock K; González-Scarano F
    Virology; 1996 Jun; 220(2):485-90. PubMed ID: 8661399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates.
    Wang Y; Rowley KJ; Booth BJ; Sloan SE; Ambrosino DM; Babcock GJ
    Antiviral Res; 2011 Aug; 91(2):187-94. PubMed ID: 21693135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human herpesvirus-6 glycoprotein H and L homologs are components of the gp100 complex and the gH external domain is the target for neutralizing monoclonal antibodies.
    Liu DX; Gompels UA; Foa-Tomasi L; Campadelli-Fiume G
    Virology; 1993 Nov; 197(1):12-22. PubMed ID: 7692666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function.
    Gonzalez-Scarano F; Janssen RS; Najjar JA; Pobjecky N; Nathanson N
    J Virol; 1985 Jun; 54(3):757-63. PubMed ID: 3889368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epitope mapping studies with neutralizing and non-neutralizing monoclonal antibodies to the G1 and G2 envelope glycoproteins of Hantaan virus.
    Wang M; Pennock DG; Spik KW; Schmaljohn CS
    Virology; 1993 Dec; 197(2):757-66. PubMed ID: 7504368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. California serogroup virus infection in a horse with encephalitis.
    Lynch JA; Binnington BD; Artsob H
    J Am Vet Med Assoc; 1985 Feb; 186(4):389. PubMed ID: 3972700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses.
    Gonzalez-Scarano F; Shope RE; Calisher CE; Nathanson N
    Virology; 1982 Jul; 120(1):42-53. PubMed ID: 7101727
    [No Abstract]   [Full Text] [Related]  

  • 36. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
    Turki I; Hammami A; Kharmachi H; Mousli M
    Mol Immunol; 2014 Feb; 57(2):66-73. PubMed ID: 24091293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tropism of bunyaviruses: evidence for a G1 glycoprotein-mediated entry pathway common to the California serogroup.
    Pekosz A; Griot C; Nathanson N; Gonzalez-Scarano F
    Virology; 1995 Dec; 214(2):339-48. PubMed ID: 8553534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organization of Germiston bunyavirus M open reading frame and physicochemical properties of the envelope glycoproteins.
    Gerbaud S; Pardigon N; Vialat P; Bouloy M
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2245-54. PubMed ID: 1402815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment.
    Papaneri AB; Wirblich C; Marissen WE; Schnell MJ
    Vaccine; 2013 Dec; 31(49):5897-902. PubMed ID: 24120673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus.
    Walsh EE; Schlesinger JJ; Brandriss MW
    J Gen Virol; 1984 Apr; 65 ( Pt 4)():761-7. PubMed ID: 6707612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.